Cite
HARVARD Citation
Pedraza, F. et al. (2016). Impact of grazoprevir and elbasvir in the treatment of hepatitis C virus–infected patients with chronic kidney disease and end‐stage renal disease. Clinical liver disease. 7 (5), pp. 112-115. [Online].